ScreenerHero

ENGN enGene Therapeutics Inc.

NAS · US · Healthcare · Biotechnology · engene.com
1.745USD-3.06%Mkt Cap: 116.94M $P/E: —

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap116.94M USD
Enterprise Value-112.42M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-117.30M USD
Revenue/Share—
Last Price1.745 USD
Fiscal Year EndOct 2025
MR QuarterJul 2026
Employees81
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.24
PEG—
EV/EBITDA0.83
EV/Revenue—
P/S—
P/B0.52
EPS (TTM)-2.07
EPS (Forward)-1.45
52W Range
1.4003% of range12.25
52W High12.25 USD
52W Low1.400 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-69.94%
ROA-52.97%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-99.24M USD
CapEx (TTM)1.49M USD
FCF Margin—
FCF Yield-52.03%
Net Debt-233.05M USD
Net Debt/EBITDA1.71
Balance Sheet
Debt/Equity0.19
Current Ratio10.21
Quick Ratio9.89
Book Value/Sh3.44 USD
Cash/Share3.97 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)3.286 USD
Upside (mean)+88.3%
Target Range2.000 USD – 5.000 USD
2.000+88.3% to mean5.000
# Analysts7
Ownership
Shares Out.67.02M
Float32.75M
Insiders0.11%
Institutions84.10%
Short Interest
Short Ratio1.7d
Short % Float2.21%
Short % Out.1.79%
Shares Short1.20M
Short (prev mo.)1.50M
Technical
SMA 501.847 (-5.5%)
SMA 2005.043 (-65.4%)
Beta-0.28
S&P 52W Chg16.45%
Avg Vol (30d)758.10K
Avg Vol (10d)905.72K
Technical Indicators
RSI (14)39.1
MACD0.0013
MACD Signal0.0247
MACD Hist.-0.0233
BB Upper2.073 USD
BB Middle1.908 USD
BB Lower1.742 USD
BB Width17.35%
ATR (14)0.0870 USD
Vol Ratio (20d)0.95x